Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The conversation discusses using a combination of DHT gel, dutasteride, pyrilutamide, and minoxidil to promote beard growth while minimizing hair loss. Users suggest consulting a doctor and considering genetic factors before proceeding.

The conversation is about using microneedling for hair loss treatment, including questions on disinfection and post-treatment care. The user mentions using oral minoxidil and finasteride, and considering dutasteride.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

The conversation is about different treatments for hair loss, including minoxidil, finasteride, RU58841, and dermarolling. The conclusion is that RU58841 and dermarolling have shown efficacy in treating hair loss through different pathways.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

The conversation is about a user struggling with hair loss despite using dutasteride, finasteride, minoxidil, and dermaneedling. The user is considering other treatments but is hesitant to use RU-58841 due to side effects and is seeking advice on alternative solutions.

The user shared a 6-month progress update on hair loss treatment using Dutasteride (0.5mg), Minoxidil (5%), and Dermanator 2. They reported improved hair density and coverage, especially in the crown/mid-scalp, and are focusing on enhancing the hairline.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

The conversation discusses the effectiveness of different concentrations and dosages of topical finasteride on scalp and serum DHT levels, comparing it to oral finasteride and noting the side effects seem to be fewer at lower dosages. Participants shared experiences and referenced a chart indicating similar scalp DHT reduction with 0.025% topical finasteride as with 1mg oral finasteride, but with fewer side effects.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

A user is seeking advice on adding dutasteride to their finasteride regimen to stop DHT-related scalp itch. They have tried selenium sulfide and ketoconazole shampoos with temporary success.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

Cialis is used to manage erectile dysfunction caused by finasteride and dutasteride, with mixed results. Some users report improvement, while others consider stopping the medication due to side effects.

A 20-year-old is considering starting dutasteride or finasteride for hair loss, with concerns about potential side effects and development. Users shared experiences with both treatments, noting that finasteride is often the first step, while dutasteride may be more effective for some, and emphasized consulting a healthcare provider.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

User reports almost 2 months on DUT and MIN for hair loss with positive results. Treatment includes 0.5mg dut (morning), 5mg oral min (night), and vitamin D and B12 supplements.

Topical dutasteride may be effective for hair loss by staying in the scalp and minimizing bloodstream absorption, potentially improving hair results and reducing side effects. The user seeks advice on its effectiveness.

After switching from finasteride to dutasteride, the user noticed new hair growth and experienced manageable shedding. They reported feeling great on dutasteride with minimal side effects, using Cialis occasionally for libido issues.

The user is considering using Tacrolimus Solution and topical Dutasteride to avoid shedding caused by Minoxidil, which they fear may lead to facial side effects. They are also concerned about scalp sensitivity and are exploring different treatment bases to manage seborrheic dermatitis.

The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.

The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

Bryan Johnson uses topical dutasteride, minoxidil, and microneedling for hair loss. Users discuss treatment effectiveness and side effects, debating topical versus oral dutasteride efficacy.

The conversation discusses the use of dutasteride and finasteride for hair loss, with a focus on starting with low doses of dutasteride to match the DHT suppression of finasteride. It highlights the longer half-life and potential side effects of dutasteride, as well as the preference for finasteride due to its availability and research backing.

Dutasteride mesotherapy involves micro injections every 3 months to reduce side effects compared to regular finasteride. The discussion focuses on its effectiveness and safety for hair loss treatment.

A user is considering a solution with 7% minoxidil, 0.25% finasteride, and 0.0125% tretinoin for hair loss, as suggested by their dermatologist. Other users share their experiences with similar treatments, noting mixed results and suggesting stronger alternatives like dutasteride.

The conversation discusses hair loss treatments, focusing on reducing scalp itching and dandruff using natural shampoos, witch hazel, and apple cider vinegar. The user also mentions using finasteride and observing potential regrowth, though it's difficult to confirm.